|
Epithelial ovarian cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Women with epithelial ovarian cancer (OC) have a higher chance to benefit from PARP inhibitor (PARPi) therapy if their tumor has a somatic or hereditary BRCA1/2 pathogenic variant.
|
31076742 |
2020 |
|
Epithelial ovarian cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this review, we discuss HR deficiency hallmarks as predictive biomarkers for platinum salt and PARP inhibitor sensitivity for selecting patients affected by TNBC or epithelial ovarian cancer who could benefit from these therapeutic options.
|
30661659 |
2019 |
|
Epithelial ovarian cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Maintenance therapy with PARP inhibitors has heralded a new era in the management of recurrent epithelial ovarian cancer.
|
31037967 |
2019 |
|
Epithelial ovarian cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tumor BRCA Test for Patients with Epithelial Ovarian Cancer: The Role of Molecular Pathology in the Era of PARP Inhibitor Therapy.
|
31653094 |
2019 |
|
Epithelial ovarian cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, our results demonstrate a proof-of-principle approach and the combination regiment holds promise in treating BRCA-wild type and PARP inhibitor-resistant EOC.
|
30444904 |
2018 |
|
Epithelial ovarian cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In this landscape, the innovative treatment with PARP inhibitors (PARPis) demonstrated an outstanding activity in EOC, and is currently changing clinical practice in BRCA mutant patients.
|
29512470 |
2018 |
|
Epithelial ovarian cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer.
|
29262321 |
2017 |
|
Epithelial ovarian cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
The integration of surgery, with a 'personalized' approach by the use of antiangiogenic agent and of PARP inhibitors is affecting survival of patients with recurrent disease and will help epithelial ovarian cancer to become a chronic disease.
|
29232464 |
2017 |
|
Epithelial ovarian cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
All clinical data have to be interpreted in the light of many changes happened in the field of EOC just in the last few years: new hystology stage classification (FIGO), new hystology types and differentiation grades classification, new therapeutic possibilities (PARP inhibitors available, also in Slovenia) and new guidelines for genetic counselling of EOC patients (National Comprehensive Cancer Network, NCCN), together with next-generation sequencing possibilities.
|
28740454 |
2017 |
|
Epithelial ovarian cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
PARP inhibitors alone and in combination with other biological agents in homologous recombination deficient epithelial ovarian cancer: From the basic research to the clinic.
|
28477743 |
2017 |
|
Epithelial ovarian cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cumulative defects in DNA repair pathways drive the PARP inhibitor response in high-grade serous epithelial ovarian cancer cell lines.
|
27374179 |
2017 |
|
Epithelial ovarian cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Tolerance and toxicity of the PARP inhibitor olaparib in older women with epithelial ovarian cancer.
|
29037805 |
2017 |
|
Epithelial ovarian cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Platinum and PARP inhibitor (PARPi) sensitivity commonly coexist in epithelial ovarian cancer (EOC) due to the high prevalence of alterations in the homologous recombination (HR) DNA repair pathway that confer sensitivity to both drugs.
|
25634215 |
2015 |
|
Epithelial ovarian cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
The promise of PARP-inhibitors(PARPis) in the management of epithelial ovarian cancer(EOC) is tempered by the fact that approximately 50% of patients with homologous recombination (HR)-proficient tumors do not respond well to these agents.
|
24798692 |
2014 |
|
Epithelial ovarian cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
PARP inhibitors exploit synthetic lethality to target epithelial ovarian cancer (EOC) with hereditary BRCA mutations and defects in homologous recombination repair (HRR).
|
24413181 |
2014 |
|
Epithelial ovarian cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
BMS-536924 sensitizes human epithelial ovarian cancer cells to the PARP inhibitor, 3-aminobenzamide.
|
19699512 |
2009 |